Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piclidenoson for Treatment of COVID-19
2021-002009-85Phase 2Completed
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Piclidenoson + standard supportive care with Placebo + standard supportive care (2 arms). Primary endpoints: Clinical benefit of piclidenoson plus standard supportive care versus placebo plus standard supportive care and Safety and tolerability of oral piclidenoson 2 mg every 12 hours. Started Jul 2021; status: completed.
02
Drugs
piclidenoson
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-002009-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002009-85.